Serviços Personalizados
Journal
Artigo
Espanhol (pdf)
Artigo em XML
Referências do artigo
Tradução automática
Enviar este artigo por emailIndicadores
Citado por SciELO 
Acessos
Links relacionados
Citado por Google 
Similares em
SciELO 
Similares em Google
Compartilhar
Permalink
Urología Colombiana
versão On-line ISSN 2027-0119
Resumo
SAENZ-RENGIFO, Dayana; PATINO, Iván D.; LOPEZ-MESA, Byron e VARELA-RAMIREZ, Rodolfo. PSA nadir as predictor of overall survival in hormone-sensitive metastatic prostate cancer. Urol. Colomb. [online]. 2025, vol.34, n.3, pp.140-146. Epub 02-Set-2025. ISSN 2027-0119. https://doi.org/10.24875/ruc.24000070.
Objective:
Androgen deprivation therapy, along with prostate-specific antigen (PSA), is used to monitor the progression of prostate cancer. This study evaluates the relationship between the PSA nadir and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with orchiectomy.
Method:
Retrospective cohort of 220 patients with mCRPC managed with orchiectomy.
Results:
A PSA nadir ≥ 0.2 ng/ml and time to nadir > 6 months are significant predictors of overall survival.
Conclusions:
PSA nadir is a useful tool as a predictor of overall survival in patients with mCRPC.
Palavras-chave : Prostate neoplasms; Prostate-specific antigen; Metastasis; Survival.
